Treatment Timeline

Treatment Progression

12-36 hours

Fever breaks.  Some cats may show improvement in appetite and energy, however others will take longer.  Effusion may continue to collect and increase for the first few days.

Day 3-5

Favorable response to treatment is noticed for most cats within this time period.  Ocular and neurological symptoms generally show improvement.

Day 7

Dyspnea and associated  thoracic effusion is typically resolved

Day 7-14

Absorption of abdominal effusion begins to be noticed -- full resolution within 1-2 weeks.  Ocular disease significantly or  fully resolved.

Day 21-28

Absorption of abdominal effusion is complete

Neurological symptoms typically show significant improvement within 24-72 hours, after which continued progress tends to be more gradual.  Click here for a case report with video timeline showing resolution of paresis.

Hematological and serum chemistry changes

10.1177_1098612X19825701-fig4.jpg

PCVs gradually return to normal levels about 6–8 weeks into treatment, with a transient dip in week 2.

Initial leukophilia (often neutrophilic) drops to normal levels within the first 2 weeks of treatment.  Some cats experience neutropenia which may persist after treatment ends.

 

Lymphopenia often resolves after a week of treatment, with fluctuating lymphocyte levels throughout treatment.  Some cats experience lymphocytosis, which may persist for several months after treatment ends.

10.1177_1098612X19825701-fig3.jpg

Globulin levels rise during the first few weeks of treatment, with a dramatic rise in week 3, roughly corresponding with the timeframe when abdominal effusions are resolving.

Albumin levels typically start low and gradually rise throughout treatment.

10.1177_1098612X19825701-fig6.jpg
10.1177_1098612X19825701-fig5.jpg
10.1177_1098612X19825701-fig7.jpg

No significant changes are seen in ALT, AST, ALP, lipase, amylase, BUN or creatinine levels are typically seen during treatment.  A few cats (particularly older cats, or cats with already compromised kidneys) will see rising BUN, creatinine and SDMA values associated with GS-441524 treatment.